CL2023002555A1 - Compuestos macrocíclicos y métodos de uso de los mismos (divisional ). - Google Patents

Compuestos macrocíclicos y métodos de uso de los mismos (divisional ).

Info

Publication number
CL2023002555A1
CL2023002555A1 CL2023002555A CL2023002555A CL2023002555A1 CL 2023002555 A1 CL2023002555 A1 CL 2023002555A1 CL 2023002555 A CL2023002555 A CL 2023002555A CL 2023002555 A CL2023002555 A CL 2023002555A CL 2023002555 A1 CL2023002555 A1 CL 2023002555A1
Authority
CL
Chile
Prior art keywords
methods
macrocyclic
eulbm
binding motif
divisional
Prior art date
Application number
CL2023002555A
Other languages
English (en)
Inventor
Fuhrmann Jakob
Fairbrother Wayne
Wu Hao
Murray Jeremy
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CL2023002555A1 publication Critical patent/CL2023002555A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/52—Cyclic peptides containing at least one abnormal peptide link with only normal peptide links in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proveen compuestos macrocíclicos que comprenden un motivo de unión a la ubiquitina ligasa E3 (EULBM) y al menos un aminoácido, y métodos para preparar y usar tales EULBM macrocíclicos para el tratamiento del cáncer o de una condición fibrótica. También se proveen inductores químicos heterobifuncionales macrocíclicos de degradación (CIDE) que comprenden un motivo de unión a la ubiquitina ligasa E3 (EULBM) y un motivo de unión a la proteína diana (TPBM) unidos por al menos un aminoácido.
CL2023002555A 2020-06-23 2023-08-29 Compuestos macrocíclicos y métodos de uso de los mismos (divisional ). CL2023002555A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063043071P 2020-06-23 2020-06-23

Publications (1)

Publication Number Publication Date
CL2023002555A1 true CL2023002555A1 (es) 2024-01-26

Family

ID=77207221

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2022003643A CL2022003643A1 (es) 2020-06-23 2022-12-19 Compuestos macrocíclicos y métodos de uso de los mismos.
CL2023002555A CL2023002555A1 (es) 2020-06-23 2023-08-29 Compuestos macrocíclicos y métodos de uso de los mismos (divisional ).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2022003643A CL2022003643A1 (es) 2020-06-23 2022-12-19 Compuestos macrocíclicos y métodos de uso de los mismos.

Country Status (17)

Country Link
US (1) US20220106361A1 (es)
EP (1) EP4168121A2 (es)
JP (1) JP2023532233A (es)
KR (1) KR20230026461A (es)
CN (1) CN115702026A (es)
AR (1) AR122707A1 (es)
AU (1) AU2021297799A1 (es)
BR (1) BR112022026364A2 (es)
CA (1) CA3185149A1 (es)
CL (2) CL2022003643A1 (es)
CO (1) CO2022018532A2 (es)
CR (1) CR20220658A (es)
IL (1) IL299163A (es)
MX (1) MX2022016454A (es)
PE (1) PE20230617A1 (es)
TW (1) TW202219056A (es)
WO (1) WO2021262731A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024020159A1 (en) * 2022-07-21 2024-01-25 Merck Sharp & Dohme Llc Macrocyclic peptides targeting kras

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4144233A (en) 1977-02-16 1979-03-13 The Dow Chemical Company Method for preparing benzo-(1,3,4)-benzotriazepines
US5185331A (en) 1991-05-14 1993-02-09 Merck & Co., Inc. Triazolobenzodiazepines
CA2340676A1 (en) * 1998-08-20 2000-03-02 Eli Lilly And Company Ring modified cyclic peptide analogs
WO2006129623A1 (ja) 2005-05-30 2006-12-07 Mitsubishi Tanabe Pharma Corporation チエノトリアゾロジアゼピン化合物及びその医薬としての用途
EP2239264A4 (en) 2007-12-28 2012-01-11 Mitsubishi Tanabe Pharma Corp ANTITUMOR AGENT
GB0919426D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
JP5524343B2 (ja) 2009-11-05 2014-06-18 グラクソスミスクライン エルエルシー ベンゾジアゼピンブロモドメイン阻害剤
RS54645B1 (en) 2009-11-05 2016-08-31 Glaxosmithkline Llc BENZODIAZEPINE AS A BROMODOMEN INHIBITOR
WO2011143651A1 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating metabolism
CN104311562B (zh) 2010-05-14 2017-07-04 达那-法伯癌症研究所 用于治疗瘤形成、炎性疾病和其他失调的组合物和方法
ES2526671T3 (es) 2010-06-22 2015-01-14 Glaxosmithkline Llc Compuestos de benzotriazoldiazepina inhibidores de bromodominios
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
WO2013106646A2 (en) 2012-01-12 2013-07-18 Yale University Compounds and methods for the inhibition of vcb e3 ubiquitin ligase
US10428026B2 (en) 2015-09-02 2019-10-01 Glaxosmithkline Intellectual Property (No.2) Limited Pyridinone dicarboxamide for use as bromodomain inhibitors
US20200354413A1 (en) * 2017-12-15 2020-11-12 Dana-Farber Cancer Institute, Inc. Stabilized peptide-mediated targeted protein degradation

Also Published As

Publication number Publication date
CA3185149A1 (en) 2021-12-30
CN115702026A (zh) 2023-02-14
JP2023532233A (ja) 2023-07-27
CL2022003643A1 (es) 2023-05-26
PE20230617A1 (es) 2023-04-14
TW202219056A (zh) 2022-05-16
IL299163A (en) 2023-02-01
AU2021297799A1 (en) 2022-12-22
MX2022016454A (es) 2023-03-06
AR122707A1 (es) 2022-09-28
BR112022026364A2 (pt) 2023-01-17
KR20230026461A (ko) 2023-02-24
US20220106361A1 (en) 2022-04-07
EP4168121A2 (en) 2023-04-26
CR20220658A (es) 2023-04-26
WO2021262731A2 (en) 2021-12-30
WO2021262731A3 (en) 2022-02-24
CO2022018532A2 (es) 2022-12-30

Similar Documents

Publication Publication Date Title
CL2023002555A1 (es) Compuestos macrocíclicos y métodos de uso de los mismos (divisional ).
CL2019002777A1 (es) Compuestos que inhiben la proteína mcl-1.
CO2021009695A2 (es) Conjugados de il-2 y métodos de uso de este
CL2021003419A1 (es) Agonistas del receptor del péptido-1 similar al glucagón
CL2021002241A1 (es) Proteínas de unión condicionalmente activadas restringidas (divisional de la solicitud no. 202000570)
BR112021017583A2 (pt) Compostos, composições e métodos para o tratamento de doença
DOP2019000020A (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
ECSP109934A (es) Compuesto - 946
BR112021020285A2 (pt) Métodos e composições para degradação de proteína alvejada
ECSP10010413A (es) Inhibidores macrociclicos de serina proteasa
BR112022004699A2 (pt) Vs-6063 em combinação com ch5126766 para o tratamento de câncer
CO2022000481A2 (es) Inhibidores de enzimas
CO2022001210A2 (es) Conjugados de il-2 y métodos de uso para tratar enfermedades autoinmunes
CO2021001277A2 (es) Inhibidores de triazol glicolato oxidasa
CL2021001739A1 (es) Inhibidores de la proteína de activación de fibroblastos.
ECSP21026485A (es) Piridazinonas y sus métodos de uso
CO2021012375A2 (es) Inhibidor de la interacción proteína-proteína wdr5 basado en anilina, método para preparar el mismo y uso del mismo
DOP2023000054A (es) Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicación de los mismos
EA202092540A1 (ru) Комбинации для лечения рака
CO2021016301A2 (es) Arn terapéutico para cáncer de ovario
AR121390A1 (es) Composiciones y métodos para tratar la deficiencia auditiva no relacionada con la edad en un sujeto humano
BR112022012280A2 (pt) Combinações
BR112022021918A2 (pt) Composições e métodos para o tratamento de fibrose cística
BR112023023578A2 (pt) Composto, composição farmacêutica compreendendo o composto e método de tratamento de uma leucemia aguda
BR112022000155A2 (pt) Composição inibidora da micromolécula pi4kiiia, seu método de preparação, e uso da mesma